MCID: CNN004
MIFTS: 45

Connective Tissue Cancer

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Cancer

MalaCards integrated aliases for Connective Tissue Cancer:

Name: Connective Tissue Cancer 12 15
Neoplasms, Connective Tissue 45 74
Neoplasm of Connective Tissues 12
Tumour of Connective Tissue 12
Connective Tissue Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:201
MeSH 45 D009372
UMLS 74 C0027656

Summaries for Connective Tissue Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in connective tissue.

MalaCards based summary : Connective Tissue Cancer, also known as neoplasms, connective tissue, is related to bone cancer and connective tissue benign neoplasm. An important gene associated with Connective Tissue Cancer is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Glioma and Chromatin Regulation / Acetylation. The drugs Dienogest and Nandrolone decanoate have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Connective Tissue Cancer

Diseases related to Connective Tissue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 bone cancer 32.1 CD99 COL1A1 EWSR1
2 connective tissue benign neoplasm 11.4
3 kaposi sarcoma 11.0
4 chondrosarcoma 11.0
5 fibrosarcoma 11.0
6 spindle cell sarcoma 11.0
7 pleural cancer 11.0
8 epithelioid sarcoma 11.0
9 zika virus infection 10.6 MDM2 TP53
10 ring chromosome 4 10.5 COL1A1 PDGFB
11 bladder sarcoma 10.5 CD99 EWSR1
12 proliferative fasciitis 10.5 SERPINA3 SMARCB1
13 cellular neurofibroma 10.5 CD34 TP53
14 undifferentiated embryonal sarcoma of the liver 10.5 CDK4 MDM2 SERPINA3
15 soft tissue sarcoma 10.5 EWSR1 MDM2 TP53
16 actinic cheilitis 10.5 MDM2 TP53
17 rhabdoid cancer 10.5 EWSR1 SMARCB1 TP53
18 extraosseous chondrosarcoma 10.5 EWSR1 FUS SMARCB1
19 retroperitoneal sarcoma 10.5 MDM2 SMARCB1
20 tibial adamantinoma 10.5 CD34 SSX1
21 testicular fibroma 10.5 CD34 CD99
22 ring chromosome 7 10.5 CDK4 MDM2 TP53
23 fibrous histiocytoma 10.5 EWSR1 FUS SERPINA3
24 nodular tenosynovitis 10.5 CD68 SERPINA3
25 dermis tumor 10.5 COL1A1 PDGFB SERPINA3
26 bone epithelioid hemangioma 10.5 CD34 EWSR1
27 bednar tumor 10.5 COL1A1 PDGFB
28 infiltrating angiolipoma 10.5 CDK4 MDM2
29 malignant fibroxanthoma 10.5 CDK4 MDM2 SERPINA3
30 kidney hemangiopericytoma 10.5 CD34 SS18
31 fibrosarcoma of bone 10.5 CDK4 MDM2 SERPINA3
32 dedifferentiated liposarcoma 10.5 CDK4 MDM2 TP53
33 vulvar sarcoma 10.5 CD34 EWSR1 SMARCB1
34 central nervous system sarcoma 10.5 CD68 SMARCB1
35 lipomatosis, multiple 10.5 CDK4 FUS MDM2
36 spindle cell lipoma 10.5 CDK4 MDM2
37 retina lymphoma 10.5 CD34 CD68
38 mesenchymal cell neoplasm 10.5 CD34 EWSR1 SMARCB1
39 scrotal carcinoma 10.5 CD68 SERPINA3 TP53
40 retinal cancer 10.5 CDK4 MDM2 TP53
41 rhabdomyosarcoma 2 10.5 CDK4 EWSR1 MDM2
42 ocular cancer 10.5 CDK4 MDM2 TP53
43 extraskeletal ewing sarcoma 10.5 CD99 EWSR1 FUS
44 kidney rhabdoid cancer 10.5 CD99 EWSR1 SMARCB1
45 grade iii astrocytoma 10.5 CDK4 MDM2 TP53
46 infiltrating lipoma 10.5 CD34 CDK4 MDM2
47 cellular schwannoma 10.5 CD34 MDM2 TP53
48 myxofibrosarcoma 10.5 FUS MDM2
49 xanthogranulomatous cholecystitis 10.5 CD68 SERPINA3 TP53
50 myxosarcoma 10.5 CD68 MDM2 TP53

Graphical network of the top 20 diseases related to Connective Tissue Cancer:



Diseases related to Connective Tissue Cancer

Symptoms & Phenotypes for Connective Tissue Cancer

GenomeRNAi Phenotypes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

27 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.89 SSX2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.89 EWSR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.89 CDK4 FUS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.89 CDK4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.89 SSX1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.89 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.89 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.89 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.89 EWSR1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.89 SSX1 SSX2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.89 EWSR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.89 FUS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.89 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.89 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.89 FUS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.89 CDK4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.89 FUS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.89 SSX1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.89 FUS
20 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.89 SSX2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.89 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.89 CDK4 EWSR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.89 CDK4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.89 EWSR1 SSX1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.89 FUS
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.89 SSX1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.89 FUS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.89 SSX2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.89 FUS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.89 EWSR1 SSX2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.89 CDK4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.89 EWSR1
33 Increased proliferation GR00094-A 8.96 SMARCB1 TP53

MGI Mouse Phenotypes related to Connective Tissue Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 CAMKMT CD34 CD68 CDK4 COL1A1 MDM2
2 liver/biliary system MP:0005370 9.87 CDK4 COL1A1 MDM2 PDGFB PECAM1 SMARCB1
3 muscle MP:0005369 9.86 CAMKMT CDK4 COL1A1 MDM2 PDGFB PECAM1
4 neoplasm MP:0002006 9.7 CD34 CDK4 COL1A1 FOXO4 MDM2 SMARCB1
5 pigmentation MP:0001186 9.35 CDK4 COL1A1 MDM2 PDGFB TP53
6 renal/urinary system MP:0005367 9.17 CAMKMT CDK4 COL1A1 MDM2 PDGFB PECAM1

Drugs & Therapeutics for Connective Tissue Cancer

Drugs for Connective Tissue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
3
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
4
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53714-56-0 657181 3911
5
Goserelin Approved Phase 4,Phase 3 65807-02-5 5311128 47725
6
Desogestrel Approved Phase 4 54024-22-5 40973
7
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
8
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 1 471-34-1
9
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 5284616 6436030
11
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 70789204 6442177
12
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
13
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
14
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
15
Zoledronic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
16
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
17
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
18
Zinc Approved, Investigational Phase 4 7440-66-6 32051
19
Ferrous fumarate Approved Phase 4 141-01-5
20
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
21
Nicotinamide Approved, Investigational Phase 4,Phase 2 98-92-0 936
22
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
23
Zinc oxide Approved Phase 4 1314-13-2
24
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
25
Letrozole Approved, Investigational Phase 4,Phase 2,Phase 1 112809-51-5 3902
26
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
27
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
28
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
29
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
30
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
31
Morphine Approved, Investigational Phase 4,Phase 2,Phase 1 57-27-2 5288826
32
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
33
Caffeine Approved Phase 4 58-08-2 2519
34
Ethanol Approved Phase 4,Phase 3 64-17-5 702
35
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
36
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
37
Misoprostol Approved Phase 4,Phase 2,Phase 3 59122-46-2 5282381
38
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 57-83-0 5994
39
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 46507594 772
40
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
41
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
42
Lithium carbonate Approved Phase 4 554-13-2
43
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
44
Enoxaparin Approved Phase 4 9005-49-6 772
45
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
46
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
47
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 56-40-6 750
48
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
50
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130

Interventional clinical trials:

(show top 50) (show all 1278)
# Name Status NCT ID Phase Drugs
1 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
2 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
3 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
4 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
5 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
6 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
7 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
8 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
9 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
10 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
11 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
12 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
13 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
14 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
15 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
16 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
17 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4 Imatinib mesylate
18 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4 Imatinib Mesylate
19 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
20 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib Completed NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
21 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
22 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
23 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
24 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
25 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
26 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
27 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
28 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
29 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
30 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
31 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
32 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
33 Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma Recruiting NCT03932071 Phase 4 Zoledronic Acid
34 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
35 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
36 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
37 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
38 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
39 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
40 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
41 Ulipristal Use in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
42 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
43 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Active, not recruiting NCT00756509 Phase 4 Nilotinib
44 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
45 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
46 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
47 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
48 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Terminated NCT00180739 Phase 4
49 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
50 Non-invasive Focal Therapy for Osteoid Osteoma Unknown status NCT02302651 Phase 2, Phase 3

Search NIH Clinical Center for Connective Tissue Cancer

Cochrane evidence based reviews: neoplasms, connective tissue

Genetic Tests for Connective Tissue Cancer

Anatomical Context for Connective Tissue Cancer

MalaCards organs/tissues related to Connective Tissue Cancer:

42
Bone, T Cells, Breast, Lung, Kidney, Liver, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Cancer:

20
Connective Tissue

Publications for Connective Tissue Cancer

Articles related to Connective Tissue Cancer:

# Title Authors Year
1
Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). ( 23446092 )
2013
2
Long-term effects of connective tissue cancer treatment. ( 15346055 )
2004

Variations for Connective Tissue Cancer

Expression for Connective Tissue Cancer

Search GEO for disease gene expression data for Connective Tissue Cancer.

Pathways for Connective Tissue Cancer

GO Terms for Connective Tissue Cancer

Cellular components related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 CAMKMT CDK4 EWSR1 FOXO4 FUS HIST2H2AA3
2 npBAF complex GO:0071564 8.96 SMARCB1 SS18

Biological processes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hyperoxia GO:0055093 9.32 CDK4 COL1A1
2 paracrine signaling GO:0038001 9.26 CD34 PDGFB
3 response to water-immersion restraint stress GO:1990785 9.16 FOXO4 MDM2
4 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
5 glomerular endothelium development GO:0072011 8.62 CD34 PECAM1

Molecular functions related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 COL1A1 EWSR1 FOXO4 FUS MDM2 PDGFB
2 platelet-derived growth factor binding GO:0048407 9.16 COL1A1 PDGFB
3 p53 binding GO:0002039 9.13 MDM2 SMARCB1 TP53

Sources for Connective Tissue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....